Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS, Richter A, Thomas D, Cook G, McInnes IB, Willicombe M, Siebert S, Orchard K, Selby R, Bowden S, Collini PJ, Pope A, Kirkham A, Kronsteiner B, Dunachie SJ, Miller P, Clay J, Hurst E, Malladi R, Kesavan M, Kinsella F, Sanderson R, Yong KL, Rea D, Parry H; PITCH Consortium, OCTAVE Collaborative Group, OCTAVE‐DUO Investigators, PROSECO Investigators; Lim SH, Snowden JA, de Silva TI. Colton H, et al. Among authors: kearns p. Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17. Br J Haematol. 2024. PMID: 39551718 Free PMC article.
The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery.
Syrimi E, Fennell E, Richter A, Vrljicak P, Stark R, Ott S, Murray PG, Al-Abadi E, Chikermane A, Dawson P, Hackett S, Jyothish D, Kanthimathinathan HK, Monaghan S, Nagakumar P, Scholefield BR, Welch S, Khan N, Faustini S, Davies K, Zelek WM, Kearns P, Taylor GS. Syrimi E, et al. Among authors: kearns p. iScience. 2021 Nov 19;24(11):103215. doi: 10.1016/j.isci.2021.103215. Epub 2021 Oct 2. iScience. 2021. PMID: 34632327 Free PMC article.
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.
Veenith T, Fisher BA, Slade D, Rowe A, Sharpe R, Thickett DR, Whitehouse T, Rowland M, Scriven J, Parekh D, Bowden SJ, Savage JS, Richards D, Bion J, Kearns P, Gates S; CATALYST Trial Investigators; CATALYST investigators. Veenith T, et al. Among authors: kearns p. BMJ Open. 2021 Nov 11;11(11):e050202. doi: 10.1136/bmjopen-2021-050202. BMJ Open. 2021. PMID: 34764169 Free PMC article.
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Fisher BA, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T, Scriven J, Parekh D, Balasubramaniam MS, Cooke G, Morley N, Gabriel Z, Wise MP, Porter J, McShane H, Ho LP, Newsome PN, Rowe A, Sharpe R, Thickett DR, Bion J, Gates S, Richards D, Kearns P; CATALYST investigators. Fisher BA, et al. Among authors: kearns p. Lancet Respir Med. 2022 Mar;10(3):255-266. doi: 10.1016/S2213-2600(21)00460-4. Epub 2021 Dec 16. Lancet Respir Med. 2022. PMID: 34922649 Free PMC article. Clinical Trial.
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T. Agathanggelou A, et al. Among authors: kearns p. Blood. 2017 Jul 13;130(2):156-166. doi: 10.1182/blood-2016-12-758219. Epub 2017 May 11. Blood. 2017. PMID: 28495793 Free article.
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Kearns P, Zwaan CM, Reinhardt D, Gibson B, Moreno L, Nysom K, Nakahara S, Huang F, Zhou W, Parasrampuria DA, Nemat S. Kearns P, et al. Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7. Br J Haematol. 2019. PMID: 30847896 Free article. Clinical Trial. No abstract available.
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
Blagden SP, Yu LM, Ellis S, Hughes H, Shaaban A, Fennelly-Barnwell J, Lythgoe MP, Cooper AM, Maignen FM, Buckland SW, Kearns PR, Brown LC; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Among authors: kearns pr. Br J Cancer. 2023 Feb;128(3):474-477. doi: 10.1038/s41416-022-02051-7. Epub 2022 Nov 24. Br J Cancer. 2023. PMID: 36434156 Free PMC article.
314 results